Corporate ActionApr 30, 2026, 04:59 PM
GTBP Registers 9.72M Shares for Resale; Faces Nasdaq Delisting Risk
AI Summary
GT Biopharma, Inc. filed an S-1 registration statement for the resale of up to 9,723,057 shares of common stock by selling stockholders, from which the company will not receive proceeds. The company received $9.4 million from the exercise of Greenshoe Rights in May 2025. GTBP faces a Nasdaq delisting risk due to its stock price falling below $1 and has substantial doubt about its ability to continue as a going concern without additional financing.
Key Highlights
- Registers up to 9,723,057 common shares for resale by selling stockholders.
- Company will not receive proceeds from the sale of these registered shares.
- Received $9.4 million gross proceeds from Greenshoe Rights exercise in May 2025.
- Nasdaq notified company of non-compliance with $1 minimum bid price rule.
- Compliance period for Nasdaq listing ends May 19, 2026.
- Closing stock price on April 29, 2026, was $0.27 per share.
- Declared a dividend of 267,749 common shares to Series L Preferred Stock holders.
- Company has substantial doubt about its ability to continue as a going concern.